Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer ...

On November 5, the US Food and Drug Administration (FDA) updated the labels for all glucagon-like peptide 1 receptor agonists (GLP-1 RA) with a warning about pulmonary aspiration during general ...

Poorer folks' access to blockbuster weight-loss drugs through Medicaid remains limited, a new KFF analysis has found. Only 13 ...

The use of glucagon-like peptide 1 (GLP-1) receptor agonists in adults with type 2 diabetes mellitus (T2DM) was not ...

For the study, investigators analyzed medical records of patients who were treated with anti-cancer medications including cytotoxic, targeted immunotherapies over a 1-year period.

For adolescents with obesity, GLP1-RA treatment is associated with a reduced risk for suicidal ideation or attempts.

SGLT2 inhibitors and GLP-1 receptor agonists exhibit renoprotective effects in patients with CKD with and without diabetes.

Kentucky, Alaska and Alabama are the three states where weight loss drugs are most used, and Hawaii, Arizona and Colorado sit ...

The use of glucagon-like peptide 1 (GLP-1) agonists in patients with inflammatory bowel disease (IBD) was associated with few ...

Rybelsus is an oral glucagon-like peptide-1 (GLP-1) agonist and sibling medication to Ozempic and Wegovy. Per a phase 3 trial, Rybelsus was found to reduce cardiovascular risk among patients with ...

The Impact of New Weight Loss Drugs on Dietetics By Carrie Dennett, MPH, RDN Today’s Dietitian Vol. 26 No. 9 P. 14 What’s changed for weight-inclusive and weight management dietitians?